Type 1 Diabetes Archives - AMSL Diabetes
1300 851 056

Resources

Back

Product Resources

Type 1 Diabetes

Mar 2026 – Long-term efficacy and safety of Control-IQ technology in younger children with type 1 diabetes in Italy (2020–2023): a longitudinal multicentre real-world study

Go to publication

Jan 2026 – Rethinking control-IQ+ technology: Simple strategies for easy optimisation

*Control IQ+ software is not available for supply in Australia at this time.

Go to publication

Aug 2025 – Daytime and nighttime glycaemic control with control-IQ technology vs. standard therapy in type 1 diabetes: a systematic review and meta-analysis with trial sequential analysis and GRADE assessment

Go to publication

Mar 2025 – Control-IQ Technology Provides Similar Glycaemic Outcomes Across Two Different Continuous Glucose Monitoring Sensors

Go to publication

Feb 2025 – One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study

Go to publication

2025 – Automated Insulin Delivery in Older Adults with Type 1 Diabetes

Go to publication

Nov 2024 – Comparison of the night-time effectiveness in achieving glycaemic targets in adults with type 1 diabetes of three advanced hybrid closed-loop systems

Go to publication

July 2024 – Evaluation of time in tight range and the glycaemia risk index in adults with type 1 diabetes using an advanced hybrid closed loop system: A 1-year real-world assessment

Go to publication

2024 – Real-World Use of Control-IQ Technology Is Associated with a Lower Rate of Severe Hypoglycaemia and Diabetic Ketoacidosis Than Historical Data: Results of the Control-IQ Observational (CLIO) Prospective Study

Go to publication

2024 – Patient Reported Outcomes (PROs) for Young Children Using the Control IQ Hybrid Closed-Loop System (CIQ)

Go to publication

Sept 2023 – Safety and Efficacy of Sustained Automated Insulin Delivery Compared With Sensor and Pump Therapy in Adults With Type 1 Diabetes at High Risk for Hypoglycaemia: A Randomised Controlled Trial

Go to publication

Aug 2023 – Smartphone Bolus Feature Increases Number of Insulin Boluses in People With Low Bolus Frequency

Go to publication

Sept 2023 – Therapy Settings Associated with Optimal Outcomes for t:slim X2 with Control-IQ Technology in Real-World Clinical Care

Go to publication

 

Apr 2023 – A Meta-Analysis of Randomised Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72

Go to publication

Mar 2023 – Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes

Go to publication

Nov 2022 – Biobehavioural Changes Following Transition to Automated Insulin Delivery: A Large Real-life Database Analysis

Go to publication

2022 – Psychosocial Benefits of Using Control-IQ Technology: Long-Term Outcomes from a Multiethnic Adult Cohort with Type 1 Diabetes

Go to publication

Apr 2021 – Closed-Loop Insulin Therapy Improves Glycaemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial

Go to publication

Mar 2021 – One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology

Go to publication

Feb 2021- A Virtual Training Program for the Tandem t:slim X2 Insulin Pump: Implementation and Outcomes

Go to publication

Jan 2021 – Real-World Patient-Reported Outcomes and Glycaemic Results with Initiation of Control-IQ Technology

Go to publication

Dec 2020 – Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes

Go to publication

Aug 2020 – A Randomised Trial of Closed-Loop Control in Children with Type 1 Diabetes

Go to publication

May 2020 – Glycaemic Outcomes of Use of Closed-Loop Control vs PLGS in Type 1 Diabetes: A Randomised Controlled Trial

Go to publication

Oct 2019 – Six-Month Randomised, Multi-Center Trial of Closed-Loop Control in Type 1 Diabetes

Go to publication

Stay informed with AMSL Diabetes

Now you can get all the latest news and updates of our products, events and resources right into your inbox.

Something went wrong. Please try again later!

Stay informed with AMSL Diabetes

Now you can get all the latest news and updates of our products, events and resources right into your inbox.

Australasian Medical & Scientific Limited is a Dexcom company
Back to top